Market Closed -
Nasdaq
04:00:00 2024-05-20 pm EDT
|
5-day change
|
1st Jan Change
|
60.6
USD
|
+1.80%
|
|
+4.68%
|
-27.42%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
627.7
|
1,471
|
3,823
|
4,336
|
8,186
|
6,354
|
-
|
-
|
Enterprise Value (EV)
1 |
531.8
|
1,142
|
3,495
|
4,163
|
8,179
|
6,320
|
5,938
|
5,974
|
P/E ratio
|
-5.03
x
|
-10.5
x
|
-16.3
x
|
-10.6
x
|
-15.3
x
|
-12.8
x
|
-14.1
x
|
-26.3
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
23.4
x
|
26.3
x
|
54.3
x
|
45.8
x
|
1,087
x
|
603
x
|
84.6
x
|
16.9
x
|
EV / Revenue
|
19.8
x
|
20.5
x
|
49.6
x
|
44
x
|
1,086
x
|
600
x
|
79
x
|
15.9
x
|
EV / EBITDA
|
-5.45
x
|
-12.4
x
|
-19
x
|
-13.1
x
|
-16.9
x
|
-14
x
|
-13.4
x
|
-31
x
|
EV / FCF
|
-
|
-
|
-18.3
x
|
-13.4
x
|
-19.7
x
|
-12.9
x
|
-11.5
x
|
-15.7
x
|
FCF Yield
|
-
|
-
|
-5.48%
|
-7.47%
|
-5.08%
|
-7.74%
|
-8.72%
|
-6.36%
|
Price to Book
|
-57.4
x
|
13
x
|
15.8
x
|
-40.3
x
|
-22
x
|
-15.3
x
|
-21
x
|
-94.5
x
|
Nbr of stocks (in thousands)
|
59,161
|
70,779
|
83,883
|
94,631
|
98,054
|
104,854
|
-
|
-
|
Reference price
2 |
10.61
|
20.78
|
45.58
|
45.82
|
83.49
|
60.60
|
60.60
|
60.60
|
Announcement Date
|
3/3/20
|
2/25/21
|
2/24/22
|
3/1/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
26.87
|
55.83
|
70.43
|
94.59
|
7.53
|
10.53
|
75.12
|
375.3
|
EBITDA
1 |
-97.57
|
-92.11
|
-184
|
-318.4
|
-484.3
|
-450.3
|
-442.5
|
-192.4
|
EBIT
1 |
-98.87
|
-93.94
|
-186.3
|
-324.2
|
-496.2
|
-467.9
|
-461.1
|
-239.8
|
Operating Margin
|
-367.97%
|
-168.27%
|
-264.54%
|
-342.75%
|
-6,589.71%
|
-4,442.11%
|
-613.76%
|
-63.89%
|
Earnings before Tax (EBT)
1 |
-121.7
|
-127.3
|
-215.3
|
-389
|
-526.2
|
-487.9
|
-488.1
|
-289
|
Net income
1 |
-121.7
|
-127.3
|
-215.3
|
-389
|
-526.2
|
-489.2
|
-471.2
|
-270
|
Net margin
|
-452.93%
|
-228%
|
-305.72%
|
-411.21%
|
-6,988.63%
|
-4,645.08%
|
-627.25%
|
-71.93%
|
EPS
2 |
-2.110
|
-1.970
|
-2.800
|
-4.330
|
-5.450
|
-4.735
|
-4.294
|
-2.302
|
Free Cash Flow
1 |
-
|
-
|
-191.4
|
-310.9
|
-415.7
|
-489.1
|
-517.9
|
-379.9
|
FCF margin
|
-
|
-
|
-271.76%
|
-328.64%
|
-5,521.24%
|
-4,643.47%
|
-689.37%
|
-101.21%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/3/20
|
2/25/21
|
2/24/22
|
3/1/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020 S1
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
7.42
|
55.6
|
1.148
|
88.97
|
2.515
|
1.957
|
4.613
|
0.867
|
0.378
|
1.672
|
0.835
|
0.9571
|
2.165
|
4.268
|
1.171
|
2.333
|
EBITDA
1 |
-
|
-20.97
|
-76.52
|
-9.467
|
-107
|
-125.4
|
-122.6
|
-120.2
|
-120.4
|
-121.1
|
-
|
-103
|
-113
|
-102.8
|
-
|
-
|
EBIT
1 |
-62.72
|
-21.7
|
-77.86
|
-10.87
|
-108.4
|
-127
|
-124.5
|
-122
|
-122.3
|
-127.4
|
-126.2
|
-116
|
-112.8
|
-108.1
|
-119.9
|
-118.5
|
Operating Margin
|
-845.28%
|
-39.04%
|
-6,781.97%
|
-12.22%
|
-4,311.77%
|
-6,491.06%
|
-2,698.31%
|
-14,077.16%
|
-32,345.24%
|
-7,620.69%
|
-15,117.96%
|
-12,122.36%
|
-5,211.41%
|
-2,532.43%
|
-10,239.79%
|
-5,077.79%
|
Earnings before Tax (EBT)
1 |
-80.19
|
-30.57
|
-89.44
|
-19.82
|
-142.3
|
-137.4
|
-131.3
|
-128.6
|
-129.4
|
-136.9
|
-135.6
|
-118.8
|
-114.8
|
-114.6
|
-113.9
|
-118.2
|
Net income
1 |
-80.19
|
-30.57
|
-89.44
|
-19.82
|
-142.3
|
-137.4
|
-131.3
|
-128.6
|
-129.4
|
-136.9
|
-135.6
|
-117.8
|
-115.8
|
-114.3
|
-111.2
|
-115.4
|
Net margin
|
-1,080.73%
|
-54.98%
|
-7,791.38%
|
-22.28%
|
-5,658.45%
|
-7,019.93%
|
-2,846.07%
|
-14,837.02%
|
-34,238.62%
|
-8,187.56%
|
-16,244.67%
|
-12,308.26%
|
-5,349.17%
|
-2,677.84%
|
-9,493.28%
|
-4,947.42%
|
EPS
2 |
-
|
-0.3600
|
-1.050
|
-0.2300
|
-1.520
|
-1.450
|
-1.380
|
-1.340
|
-1.350
|
-1.380
|
-1.330
|
-1.175
|
-1.153
|
-1.075
|
-1.168
|
-1.103
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/6/20
|
2/24/22
|
5/4/22
|
8/4/22
|
11/3/22
|
3/1/23
|
5/4/23
|
8/3/23
|
11/2/23
|
2/27/24
|
5/8/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
95.9
|
328
|
329
|
173
|
7.45
|
33.9
|
417
|
381
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-191
|
-311
|
-416
|
-489
|
-518
|
-380
|
ROE (net income / shareholders' equity)
|
-
|
-112%
|
-121%
|
-572%
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-31.3%
|
-41.9%
|
-57.2%
|
-80.7%
|
-86.9%
|
-46.6%
|
Assets
1 |
-
|
-
|
687.6
|
928
|
919.5
|
605.9
|
542.4
|
579.6
|
Book Value Per Share
2 |
-0.1800
|
1.600
|
2.880
|
-1.140
|
-3.800
|
-3.950
|
-2.890
|
-0.6400
|
Cash Flow per Share
2 |
-
|
-
|
-
|
-3.330
|
-4.290
|
-2.900
|
-1.520
|
-
|
Capex
1 |
-
|
-
|
48.9
|
11.3
|
1.42
|
0.65
|
16
|
35.2
|
Capex / Sales
|
-
|
-
|
69.39%
|
11.98%
|
18.8%
|
6.17%
|
21.35%
|
9.37%
|
Announcement Date
|
3/3/20
|
2/25/21
|
2/24/22
|
3/1/23
|
2/27/24
|
-
|
-
|
-
|
Last Close Price
60.6
USD Average target price
93.06
USD Spread / Average Target +53.56% Consensus |
1st Jan change
|
Capi.
|
---|
| -27.42% | 6.35B | | +9.58% | 115B | | +12.41% | 107B | | -2.59% | 21.6B | | -12.38% | 22.31B | | -5.29% | 19.19B | | -3.35% | 18.23B | | -38.57% | 17.62B | | +7.51% | 14.26B | | +35.67% | 12.37B |
Bio Therapeutic Drugs
|